PharmiWeb
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX)
EQS-News: Defence Therapeutics Inc. / Key word(s): MiscellaneousDEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE ...
6 days ago